Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease

Fig. 1

Body weight neutral dose of acyl-GIP in LDLR-/- mice. (A) Body weight, (B) change of body composition, (C) cumulative food intake, (D) fasting blood glucose, (E) interperitoneal glucose tolerance and (F) fasting insulin levels of male LDLR-/- mice treated daily with either vehicle or acyl-GIP via subcutaneous injections for 27 days. n = 7. Except for ipGTT (performed at study day 21), plasma parameters were measured from sac blood at study end (day 27). Data represent means ± SEM

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840